Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepivacaine vs Articaine for IANB in Symptomatic Irreversible Pulpitis
NCT04822415Completed
- Sponsor
- Cairo University
- Start
- Dec 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of mepivacaine in irreversible pulpitis (2 arms), sponsored by Cairo University. Primary endpoint: Anaesthetic success. Started Dec 2014; status: completed.
02
Drugs
mepivacaine
03
Conditions
irreversible pulpitis
Beyond the preview
Go deeper on NCT04822415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04822415.